BLUE Stock Overview
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases.
bluebird bio, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$5.77|
|52 Week High||US$25.39|
|52 Week Low||US$2.87|
|1 Month Change||-2.20%|
|3 Month Change||39.37%|
|1 Year Change||-69.60%|
|3 Year Change||-93.33%|
|5 Year Change||-95.54%|
|Change since IPO||-78.56%|
Recent News & Updates
Bluebird bio names interim finance chief
Gene therapy developer bluebird bio, Inc. (NASDAQ:BLUE) has named Katherine Breedis, formerly the Chief Financial Officer Consultant at Danforth Advisors, as the company’s interim Chief Financial Officer replacing the outgoing CFO Jason Cole. Ms. Breedis has also been named as BLUE’s principal financial officer and principal accounting officer, and her appointments will take effect on Oct. 14 when Mr. Cole departs. Ms. Breedis, who has worked as a CFO consultant for Danforth since Jul. 2021, served as a consultant to BLUE after the company struck a consulting agreement with the advisory firm in May. Mr. Cole’s departure came less than a month after the FDA approved BLUE’s β-thalassemia therapy Zynteglo in August, making it the priciest treatment in history at the time.
Bluebird bio jumps 17% on FDA approval of new gene therapy
The commercial-stage biotech bluebird bio, Inc. (NASDAQ:BLUE) added ~17% pre-market Monday after the company announced the FDA approval of its gene therapy Skysona to address the impact of a rare neurodegenerative disease called cerebral adrenoleukodystrophy (CALD). According to the late Friday press release, the drug, also known as elivaldogene autotemcel (eli-cel), will be indicated in the U.S. to slow the progression of neurologic dysfunction in boys aged 4-17 with early, active CALD. With the FDA approving Skysona under the agency’s accelerated approval pathway, BLUE has agreed to deliver long-term clinical data on the treatment to the regulator, including data from an ongoing long-term follow-up study and commercially treated patients. The company expects the drug to be commercially available by the end of 2022 at a list price of $3.0M. Concurrently, BLUE confirmed that the FDA had lifted the clinical hold on the eli-cel development program. In August, Cambridge, Massachusetts-based biotech won FDA approval for another gene therapy known as Zynteglo for β-thalassemia which it priced at $2.8M.
|BLUE||US Biotechs||US Market|
Return vs Industry: BLUE underperformed the US Biotechs industry which returned -27.4% over the past year.
Return vs Market: BLUE underperformed the US Market which returned -22.1% over the past year.
|BLUE Average Weekly Movement||16.5%|
|Biotechs Industry Average Movement||11.1%|
|Market Average Movement||6.9%|
|10% most volatile stocks in US Market||15.8%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: BLUE is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 17% a week.
Volatility Over Time: BLUE's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company’s clinical study program includes HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia.
bluebird bio, Inc. Fundamentals Summary
|BLUE fundamental statistics|
Is BLUE overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|BLUE income statement (TTM)|
|Cost of Revenue||US$323.29m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-6.58|
|Net Profit Margin||-8,333.90%|
How did BLUE perform over the long term?See historical performance and comparison